Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Meanwhile, Tango tries again in PRMT5.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
The company abandons TNG908, but is still all in on the troubled target.
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
But Repare and Black Diamond still have rebuilding to do.